Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome

Fig. 7

Cenerimod treatment reduces autoantibodies within the salivary gland in the MRL/lpr mouse model. Quantification of salivary gland B cell activating factor (BAFF) protein (ng/SG) (A), IL-10 protein (pg/SG) (B), activation-induced cytidine deaminase (AID) protein (pg/SG) (C) and CXCL13 protein (pg/SG) (D). Quantification of salivary gland (E) and plasma (F) anti-SSB (OD 450 nm) and anti-dsDNA antibodies (OD 405 nm). Each data point represents the measurement of individual animals at the end of the study (week 11); horizontal line indicates the median, the box indicates the upper and lower quartiles and the whiskers indicate the minimum and maximum range; *p < 0.05, **p < 0.01, ****p < 0.0001 vs. vehicle group (Mann-Whitney test). SG, salivary gland; OD, optical density

Back to article page